Triple Mycobacterial ATP-synthase mutations impedes Bedaquiline binding: Atomistic and structural perspectives.
Adenosine Triphosphatases
/ antagonists & inhibitors
Antitubercular Agents
/ chemistry
Binding Sites
/ drug effects
Computational Biology
Diarylquinolines
/ chemistry
Enzyme Inhibitors
/ chemistry
Microbial Sensitivity Tests
Models, Molecular
Molecular Structure
Mutation
Mycobacterium tuberculosis
/ drug effects
Tuberculosis, Multidrug-Resistant
/ drug therapy
Bedaquiline
F(1)F(0)-ATP synthase
Molecular dynamic simulations
Multi-Drug resistant TB
Mycobacterium tuberculosis
Journal
Computational biology and chemistry
ISSN: 1476-928X
Titre abrégé: Comput Biol Chem
Pays: England
ID NLM: 101157394
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
received:
21
06
2019
revised:
06
01
2020
accepted:
13
01
2020
pubmed:
26
1
2020
medline:
7
1
2021
entrez:
26
1
2020
Statut:
ppublish
Résumé
Bedaquiline (BDQ) has demonstrated formidable bactericidal activity towards Mycobacterium tuberculosis (Mtb) in the treatment of multi-drug resistant (MDR) and extensively drug resistant (XDR) tuberculosis (TB). BDQ elicits its therapeutic function by halting the ionic shuttle of Mtb via mycobacterial F
Identifiants
pubmed: 31981966
pii: S1476-9271(19)30555-9
doi: 10.1016/j.compbiolchem.2020.107204
pii:
doi:
Substances chimiques
Antitubercular Agents
0
Diarylquinolines
0
Enzyme Inhibitors
0
bedaquiline
78846I289Y
Adenosine Triphosphatases
EC 3.6.1.-
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
107204Informations de copyright
Copyright © 2020 Elsevier Ltd. All rights reserved.